Please login to the form below

Not currently logged in
Email:
Password:

Dr Engelbert Tjeenk Willink joins Allecra Therapeutics

The French pharma company has also appointed Dr Leon Hooftman

Dr Engelbert Allecra Therapeutics has appointed Dr Engelbert Tjeenk Willink as chairman of the board as the company enters its next phase of development.

Previously a member of the board of managing directors at Boehringer Ingelheim GmbH, Willink (pictured right) brings over 25 years experience within the pharmaceutical industry.

He said: “Allecra is a dynamic company with the potential to make a significant impact on the growing and widespread epidemic of drug-resistant bacterial infections.


“I am delighted to have the opportunity to contribute towards its success.”

Dr Leon HooftmanDr Leon Hooftman also joins Allecra as its new chief medical officer (CMO), bringing over 20 years of experience in biopharmaceutical drug development.

Most recently serving as CMO for Polyphor, Hooftman (pictured left) has held several senior positions for the likes of Celltech Group plc and Chroma Therapeutics.

He said: “Allecra is working directly on Gram-negative resistant infections in the hospital, an area of urgent unmet medical need recently highlighted by both the World Health Organization (WHO) and by the US Center for Disease Control (CDC).

"Allecra’s technology provides an important new treatment for hospital clinicians who are grappling with these types of infection.”

Hooftman’s new role will see him focus on combating multi drug-resistant Gram-negative bacterial infections.

Nicholas Benedict, CEO at Allecra, said: “The appointments of Bert and Leon mark a watershed in the development of Allecra.

“Regulatory authorities have recognised the potential that Allecra’s novel antibiotic may contribute towards solving the crisis of resistant bacterial infections, and out lead development programme has been significantly expedited.

“With these new appointments, Allecra is strengthening its expertise as the company advances its development activities for a potentially important new antibiotics treatment for patients.”

7th April 2017

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

EU health fund
An EU emergency health fund to limit the impact of future crises
Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU...
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...

Infographics